Diabetes-Induced Mechanical Hyperalgesia Involves Spinal Mitogen-Activated Protein Kinase Activation in Neurons and Microglia via N-Methyl-D-aspartate-Dependent Mechanisms

Molecular mechanisms underlying diabetes-induced painful neuropathy are poorly understood. We have demonstrated, in rats with streptozotocin-induced diabetes, that mechanical hyperalgesia, a common symptom of diabetic neuropathy, was correlated with an early increase in extracellular signal-regulated protein kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) phosphorylation in the spinal cord and dorsal root ganglion at 3 weeks after induction of diabetes. This change was specific to hyperalgesia because nonhyperalgesic rats failed to have such an increase. Immunoblot analysis showed no variation of protein levels, suggesting a post-translational regulation of the corresponding kinases. In diabetic hyperalgesic rats, immunocytochemistry revealed that all phosphorylated mitogen-activated protein kinases (MAPKs) colocalized with both the neuronal (NeuN) and microglial (OX42) cell-specific markers but not with the astrocyte marker [glial fibrillary acidic protein (GFAP)] in the superficial dorsal horn-laminae of the spinal cord. In these same rats, a 7-day administration [5 μg/rat/day, intrathecal (i.t.)] of 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580), and anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), which inhibited MAPK kinase, p38, and JNK, respectively, suppressed mechanical hyperalgesia, and decreased phosphorylation of the kinases. To characterize the cellular events upstream of MAPKs, we have examined the role of the NMDA receptor known to be implicated in pain hypersensitivity. The prolonged blockade of this receptor during 7 days by (5R, 10S)-(+)-5-methyl-10, 11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-10-imine hydrogen maleate (MK801; 5 μg/rat/day, i.t.), a noncompetitive NMDA receptor antagonist, reversed hyperalgesia developed by diabetic rats and blocked phosphorylation of all MAPKs. These results demonstrate for the first time that NMDA receptor-dependent phosphorylation of MAPKs in spinal cord neurons and microglia contribute to the establishment and longterm maintenance of painful diabetic hyperalgesia and that these kinases represent potential targets for pain therapy.

[1]  C. Woolf,et al.  ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model , 2005, Pain.

[2]  Yi Dai,et al.  Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats , 2004, The European journal of neuroscience.

[3]  Yi Dai,et al.  Role of Mitogen-Activated Protein Kinase Activation in Injured and Intact Primary Afferent Neurons for Mechanical and Heat Hypersensitivity after Spinal Nerve Ligation , 2004, The Journal of Neuroscience.

[4]  C. Woolf,et al.  Ionotropic and Metabotropic Receptors, Protein Kinase A, Protein Kinase C, and Src Contribute to C-Fiber-Induced ERK Activation and cAMP Response Element-Binding Protein Phosphorylation in Dorsal Horn Neurons, Leading to Central Sensitization , 2004, The Journal of Neuroscience.

[5]  S. Medicherla,et al.  Antinociceptive action of a p38α MAPK inhibitor, SD-282, in a diabetic neuropathy model , 2004, Pain.

[6]  S. Koizumi,et al.  Activation of p38 mitogen‐activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury , 2004, Glia.

[7]  N. Calcutt,et al.  Activation of p38 mitogen‐activated protein kinase in spinal microglia is a critical link in inflammation‐induced spinal pain processing , 2003, Journal of neurochemistry.

[8]  J. Deleo,et al.  Inhibition of Microglial Activation Attenuates the Development but Not Existing Hypersensitivity in a Rat Model of Neuropathy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[9]  J. Pouysségur,et al.  Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. , 2003, Biochemical pharmacology.

[10]  C. Svensson,et al.  Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE2 release and thermal hyperalgesia , 2003, Neuroreport.

[11]  C. Woolf,et al.  p38 Mitogen-Activated Protein Kinase Is Activated after a Spinal Nerve Ligation in Spinal Cord Microglia and Dorsal Root Ganglion Neurons and Contributes to the Generation of Neuropathic Pain , 2003, The Journal of Neuroscience.

[12]  L. Sorkin,et al.  Tumor Necrosis Factor-α Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons , 2003, The Journal of Neuroscience.

[13]  K. Lee,et al.  Identification of MEK1 as a novel target for the treatment of neuropathic pain , 2003, British journal of pharmacology.

[14]  D. Chuang,et al.  Regulation of c‐Jun N‐terminal kinase, p38 kinase and AP‐1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection , 2003, Journal of neurochemistry.

[15]  C. Hansel,et al.  The Making of a Complex Spike: Ionic Composition and Plasticity , 2002, Annals of the New York Academy of Sciences.

[16]  D. Tomlinson,et al.  Inhibition of p38 MAP Kinase Corrects Biochemical and Neurological Deficits in Experimental Diabetic Neuropathy , 2002, Annals of the New York Academy of Sciences.

[17]  C. Woolf,et al.  p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia , 2002, Neuron.

[18]  J. Pouysségur,et al.  Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. , 2002, European journal of biochemistry.

[19]  F. Cerveró,et al.  Activation of spinal extracellular signaling-regulated kinase-1 and -2 by intraplantar carrageenan in rodents , 2002, Neuroscience Letters.

[20]  Martin Koltzenburg,et al.  Molecular mechanisms of cancer pain , 2002, Nature Reviews Cancer.

[21]  C. Woolf,et al.  ERK MAP Kinase Activation in Superficial Spinal Cord Neurons Induces Prodynorphin and NK-1 Upregulation and Contributes to Persistent Inflammatory Pain Hypersensitivity , 2002, The Journal of Neuroscience.

[22]  A. Boulton,et al.  A role for mitogen‐activated protein kinases in the etiology of diabetic neuropathy , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  B. Winkelstein,et al.  Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment , 2001, The Journal of comparative neurology.

[24]  Steven F. Maier,et al.  Glial activation: a driving force for pathological pain , 2001, Trends in Neurosciences.

[25]  A. Eschalier,et al.  Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain , 2000, Brain Research.

[26]  P. D. Drew,et al.  Inhibition of microglial cell activation by cortisol , 2000, Brain Research Bulletin.

[27]  C. Woolf,et al.  Neuronal plasticity: increasing the gain in pain. , 2000, Science.

[28]  Gary Brewer,et al.  Regulation of Cyclooxygenase 2 mRNA Stability by the Mitogen-Activated Protein Kinase p38 Signaling Cascade , 2000, Molecular and Cellular Biology.

[29]  T. Jensen,et al.  Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action , 1999, PAIN®.

[30]  C. Woolf,et al.  Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity , 1999, Nature Neuroscience.

[31]  T. Dawson,et al.  Glutamate-stimulated calcium activation of Ras/Erk pathway mediated by nitric oxide. , 1999, Diabetes research and clinical practice.

[32]  J. Priestley,et al.  Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. , 1999, Diabetes.

[33]  M. Malcangio,et al.  A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats , 1998, Pain.

[34]  J. Kocsis,et al.  Peripheral Axotomy Induces Long-Term c-Jun Amino-Terminal Kinase-1 Activation and Activator Protein-1 Binding Activity by c-Jun and junD in Adult Rat Dorsal Root Ganglia In Vivo , 1998, The Journal of Neuroscience.

[35]  K. Fukunaga,et al.  Role of MAP kinase in neurons , 1998, Molecular Neurobiology.

[36]  S. Maier,et al.  Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat , 1997, Pain.

[37]  A. Eschalier,et al.  Daily insulin treatment relieves long-term hyperalgesia in streptozocin diabetic rats. , 1996, Neuroreport.

[38]  E. Peles,et al.  Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions , 1995, Nature.

[39]  A. Eschalier,et al.  A method to perform direct transcutaneous intrathecal injection in rats. , 1994, Journal of pharmacological and toxicological methods.

[40]  A. Eschalier,et al.  Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain , 1993, Pain.

[41]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[42]  S. Papson,et al.  “Model” , 1981 .

[43]  R. Lo,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957 .

[44]  L. Sorkin,et al.  Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  C. Widmann,et al.  Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. , 1999, Physiological reviews.

[46]  L. O. Randall,et al.  A method for measurement of analgesic activity on inflamed tissue. , 1957, Archives internationales de pharmacodynamie et de therapie.